Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis.
ACE2
COVID-19
RBD
affinity
maturation
nanobody
neutralization
receptor-binding domain
spike
yeast
Journal
Cell chemical biology
ISSN: 2451-9448
Titre abrégé: Cell Chem Biol
Pays: United States
ID NLM: 101676030
Informations de publication
Date de publication:
16 09 2021
16 09 2021
Historique:
received:
09
01
2021
revised:
06
04
2021
accepted:
27
05
2021
pubmed:
26
6
2021
medline:
23
9
2021
entrez:
25
6
2021
Statut:
ppublish
Résumé
There is widespread interest in facile methods for generating potent neutralizing antibodies, nanobodies, and other affinity proteins against SARS-CoV-2 and related viruses to address current and future pandemics. While isolating antibodies from animals and humans are proven approaches, these methods are limited to the affinities, specificities, and functional activities of antibodies generated by the immune system. Here we report a surprisingly simple directed evolution method for generating nanobodies with high affinities and neutralization activities against SARS-CoV-2. We demonstrate that complementarity-determining region swapping between low-affinity lead nanobodies, which we discovered unintentionally but find is simple to implement systematically, results in matured nanobodies with unusually large increases in affinity. Importantly, the matured nanobodies potently neutralize both SARS-CoV-2 pseudovirus and live virus, and possess drug-like biophysical properties. We expect that our methods will improve in vitro nanobody discovery and accelerate the generation of potent neutralizing nanobodies against diverse coronaviruses.
Identifiants
pubmed: 34171229
pii: S2451-9456(21)00264-6
doi: 10.1016/j.chembiol.2021.05.019
pmc: PMC8223476
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Complementarity Determining Regions
0
Epitopes
0
Single-Domain Antibodies
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1379-1388.e7Subventions
Organisme : NIAID NIH HHS
ID : R21 AI152865
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM136300
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG050598
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM103297
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI151588
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG059723
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.